MedTrace Logo

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2025-04-08

No results posted yet for this study

Summary

The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.

Conditions

  • IgA Nephropathy (IgAN)
  • Renal and Urinary Disorders
  • Berger Disease

Interventions

DRUG

Atacicept 150 mg

The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½" 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec

Sponsors & Collaborators

  • Vera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Zeeshan Khawaja · Vice President, Clinical Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2028-05-31
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06674577 on ClinicalTrials.gov